|
|
| |
|
| |
IriTech has been developing its patent pending
technology for over a decade with tremendous results, emerging as one of very
few companies in the world that offer an iris biometrics solution. IriTech's innovations in drug pre-screening
and iris identification are significantly differentiated from competing
products. On the drug pre-screening
front, unlike traditional testing techniques, such as urine testing, our drug
pre-screening technologies require no bodily fluids, lack reagents, provide
faster results, and are more sensitive, cost-effective, and tamper
resistant. Additionally, in contrast
with other pupil-analysis players, IriTech's unique technology does not require
a baseline, tests both eyes simultaneously, and evaluates over 40 parameters.
In iris biometrics, IriTech has built upon key developments
in the industry to create an iris biometric solution that is more accurate and
cost-effective than the competition. IriTech has patented it iris-imaging techniques, and filed a patent for
stereo facial recognition.
The company's technology development offers
levels of cost-savings and accuracy never before experienced in the
drugs-of-abuse (DAT) and biometrics industries. For example, in the DAT space, IriTech's drug testing solutions
facilitate savings of up to 80 percent with significantly increased accuracy
rates over traditional urine analysis and hair tests. In biometrics, our iris recognition capability
boasts higher accuracy rates than the nearest competitor and is approximately
60 percent more economical. IriTech¡¯s approach to iris biometrics is based on a
Variable Multisector Method. This methodology maps both eyes, focuses on the
permanent portion of the iris, and considers the shape and position of the
lacuna, ANW geometry (shape around the border of the inner iris structure), and
pupil movement to lead to a superior and more accurate solution.
|
|
| |
|
|
